Data / Drug companies / Pfizer Ireland Pharmaceuticals Unlimited Company
Pfizer Ireland Pharmaceuticals Unlimited Company: 46 products in the FDA NDC directory, labeler code 42816
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Pfizer Ireland Pharmaceuticals Unlimited Company (labeler code 42816) lists 46 products in the FDA National Drug Code Directory. By type: 46 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on April 3, 2026.
The request: Watch Pfizer Ireland Pharmaceuticals Unlimited Company (FDA labeler code 42816): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 42816
- Products in commercial distribution
- 46
- Packages
- 46
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 9
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- October 16, 1981
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 46 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 46 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 8 | 17.4% |
| Capsule, extended release | 7 | 15.2% |
| Tablet, sugar coated | 7 | 15.2% |
| Tablet | 7 | 15.2% |
| Tablet, extended release | 7 | 15.2% |
| Tablet, film coated | 7 | 15.2% |
| Powder | 1 | 2.2% |
| Tablet, film coated, extended release | 1 | 2.2% |
| Tablet, for suspension | 1 | 2.2% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Norgestrel | 42816-7717 | Tablet | Drugs for further processing | April 3, 2026 |
| Ziprasidone | 42816-0131 | Capsule | Drugs for further processing | March 13, 2026 |
| Ziprasidone | 42816-1933 | Capsule | Drugs for further processing | March 12, 2025 |
| Ziprasidone | 42816-1329 | Capsule | Drugs for further processing | March 12, 2025 |
| Ziprasidone | 42816-1134 | Capsule | Drugs for further processing | March 12, 2025 |
| Apixaban | 42816-1028 | Tablet, for suspension | Drugs for further processing | January 22, 2025 |
| Norgestrel | 42816-8101 | Tablet | Drugs for further processing | November 28, 2022 |
| Alprazolam | 42816-0066 | Tablet, extended release | Drugs for further processing | March 24, 2022 |
| Alprazolam | 42816-0059 | Tablet, extended release | Drugs for further processing | March 15, 2022 |
| Alprazolam | 42816-0094 | Tablet | Drugs for further processing | March 8, 2022 |
| Alprazolam | 42816-0057 | Tablet, extended release | Drugs for further processing | March 2, 2022 |
| Alprazolam | 42816-0068 | Tablet, extended release | Drugs for further processing | February 11, 2022 |
| Tofacitinib | 42816-0501 | Tablet, film coated, extended release | Drugs for further processing | November 14, 2021 |
| Triazolam | 42816-0017 | Tablet | Drugs for further processing | October 1, 2021 |
| Apixaban | 42816-0894 | Tablet, film coated | Drugs for further processing | June 26, 2017 |
| Apixaban | 42816-0893 | Tablet, film coated | Drugs for further processing | June 12, 2017 |
| Propranolol hydrochloride | 42816-0479 | Capsule, extended release | Drugs for further processing | January 27, 2017 |
| Propranolol hydrochloride | 42816-0473 | Capsule, extended release | Drugs for further processing | January 27, 2017 |
| Propranolol hydrochloride | 42816-0471 | Capsule, extended release | Drugs for further processing | January 27, 2017 |
| Propranolol hydrochloride | 42816-0470 | Capsule, extended release | Drugs for further processing | January 27, 2017 |
| Conjugated estrogens | 42816-0101 | Powder | Drugs for further processing | August 28, 2015 |
| Desvenlafaxine succinate | 42816-1210 | Tablet, extended release | Drugs for further processing | November 15, 2014 |
| Ziprasidone hydrochloride | 42816-2004 | Capsule | Drugs for further processing | January 1, 2013 |
| Ziprasidone hydrochloride | 42816-2003 | Capsule | Drugs for further processing | January 1, 2013 |
| Ziprasidone hydrochloride | 42816-2002 | Capsule | Drugs for further processing | January 1, 2013 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.